Supernus Pharmaceuticals, Inc. (SUPN) Stock Price

SUPNStock
$45.36+0.51%52W
Market Cap$2.64B
P/E43.28x
PEG Ratio
Div yield
Beta0.56

SUPN Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-21.39%
Price vs S&P 500 (4W)-8.54%
VGM Score39.93
P/E Ratio (Annual)43.28x

SUPN Earnings Surprise History

Q2 250.91est. 0.47
Q3 250.61est. 0.82
Q4 250.88est. 0.28
Q1 260.21est. 0.28
Q2 260.53est. 0.51

SUPN Analyst Recommendations

May 2026
Jun 2026
Jul 2026
Aug 2026
4.17
4.17
4.17
4.17

Industry Peers — Pharmaceuticals(571)

SymbolValue ScoreGrowth ScoreMomentum ScorePrice
SUPNSupernus Pharmaceuticals, Inc.
CDD$45.36
LLYEli Lilly & Co.DBB$1233.66
JNJJohnson & JohnsonDCB$273.14
ABBVABBVIE INC.DCB$265.79
MRKMerck & Co., Inc.DCA$156.45
NVSNovartis AGCCC$159.98
AZNAstraZeneca PLCCBC$169.66
NVONovo-Nordisk A/SBCC$48.66
ABTAbbott LaboratoriesCCB$116.13
PFEPfizer Inc.CDC$28.57
VRTXVertex Pharmaceuticals IncDCB$552.85

About Supernus Pharmaceuticals, Inc.

Supernus Pharmaceuticals is a specialty pharmaceutical company focused on developing and commercializing treatments for central nervous system disorders, including neurological and psychiatric conditions. Its portfolio of eight marketed products addresses key indications such as epilepsy, migraine, ADHD, Parkinson's disease complications, and dystonia. The company serves underserved patient populations within the neuroscience space.